For human epidermal growth factor receptor 2 (HER2) + or triple-negative (TN) breast cancer, NAC can provide doctors with more in vivo information regarding drug sensitivity, a so-called individual drug-sensitive platform (6). Here, ERBB2 is linked to breast cancer.